Drug intelligence / Profile preview

V160

Development stage: Phase 2
Lead developer: Merck
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
Administration: Intramuscular, Transdermal

Overview

V160 is a conditionally replication-defective viral vaccine candidate developed for the prevention of human cytomegalovirus (HCMV) infection. It is designed to elicit an immune response against HCMV, particularly targeting glycoprotein B, and is manufactured using adult retinal pigment epithelial cells (ARPE-19). Clinical studies have shown that V160 is immunogenic and well tolerated in healthy adults, though efficacy endpoints in phase 2 trials were not met. The vaccine aims to reduce CMV shedding and may improve immune control of viral replication after infection[1][2][4].

Beyond the preview

Go deeper on V160.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V160.

Explore the full profile